US EditionPublished • loading... • Updated
N.C. emerges as focal point in national obesity-drug manufacturing race
Summary by The News & Observer
1 Articles
1 Articles
N.C. emerges as focal point in national obesity-drug manufacturing race
North Carolina sits at the center of soaring demand for GLP-1 weight-loss drugs, with Novo Nordisk and Eli Lilly operating major production sites across the Triangle and beyond. The rivals have invested billions and hired thousands as weekly injectables like Ozempic, Wegovy, Mounjaro and Zepbound reshape global pharma. Lilly now leads market share as Novo retrenches.
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
